Form 4: Apogee Therapeutics Insider Sells Shares Under 10b5-1 Plan

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc., reported the sale of 26,400 shares of common stock executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Carl Dambkowski, Chief Medical Officer at Apogee Therapeutics, Inc., sold 26,400 shares of common stock on June 22, 2026.
• The sale was conducted under a Rule 10b5-1 trading plan established on September 22, 2025.
• The shares were sold at a weighted average price of $132.60, with individual transactions ranging from $132.550 to $132.645.
• Following this transaction, Dambkowski beneficially owns 179,248 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the reported stock sale was executed under a pre-arranged Rule 10b5-1 trading plan, which is a standard and legally protected method for insiders to diversify their holdings.

Negatives

• Insider selling can sometimes be perceived negatively by the market, although this sale was conducted under a pre-established trading plan.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common and are designed to provide an affirmative defense against allegations of insider trading by allowing executives to sell shares at predetermined times and prices. This filing indicates standard executive compensation and liquidity management practices within the biotechnology sector.

Stakeholder Impact

• Shareholders: The sale by a key executive might be monitored, but the pre-arranged nature of the trade under a 10b5-1 plan mitigates concerns about insider trading. The remaining beneficial ownership by the executive still indicates continued commitment.

Key Dates

Keywords

Form 4, Insider Trading, Rule 10b5-1, Apogee Therapeutics, Stock Sale, Chief Medical Officer, Beneficial Ownership